Eyenovia’s (EYEN) “Neutral” Rating Reaffirmed at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH reaffirmed their neutral rating on shares of Eyenovia (NASDAQ:EYEN) in a research report sent to investors on Monday,Benzinga reports.

Several other research analysts have also recently weighed in on EYEN. HC Wainwright cut shares of Eyenovia from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $12.00 to $2.00 in a research note on Monday. William Blair restated a “market perform” rating on shares of Eyenovia in a research report on Friday. Finally, Brookline Capital Management restated a “hold” rating on shares of Eyenovia in a research report on Friday.

Eyenovia Trading Up 8.9 %

Shares of EYEN stock opened at $0.11 on Monday. Eyenovia has a 12-month low of $0.09 and a 12-month high of $2.57. The company has a current ratio of 0.74, a quick ratio of 0.27 and a debt-to-equity ratio of 0.58. The firm’s 50 day moving average is $0.48 and its 200 day moving average is $0.70. The stock has a market capitalization of $7.11 million, a P/E ratio of -0.15 and a beta of 1.75.

Eyenovia (NASDAQ:EYEN) last issued its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%. During the same period in the previous year, the company earned ($0.18) EPS. Research analysts expect that Eyenovia will post -0.5 earnings per share for the current year.

Insider Buying and Selling at Eyenovia

In related news, CEO Michael M. Rowe purchased 50,000 shares of Eyenovia stock in a transaction on Monday, August 26th. The shares were bought at an average cost of $0.57 per share, for a total transaction of $28,500.00. Following the acquisition, the chief executive officer now owns 82,927 shares in the company, valued at approximately $47,268.39. The trade was a 151.85 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 7.10% of the stock is currently owned by insiders.

Institutional Trading of Eyenovia

A number of large investors have recently made changes to their positions in the business. Nations Financial Group Inc. IA ADV increased its holdings in shares of Eyenovia by 24.4% in the 2nd quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock worth $30,000 after buying an additional 10,000 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Eyenovia during the 2nd quarter worth about $26,000. Ground Swell Capital LLC purchased a new position in shares of Eyenovia during the 2nd quarter worth about $27,000. Financial Management Network Inc. purchased a new position in shares of Eyenovia during the 3rd quarter worth about $39,000. Finally, SkyView Investment Advisors LLC purchased a new position in shares of Eyenovia during the 2nd quarter worth about $87,000. 25.84% of the stock is currently owned by institutional investors.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.